Oracle Investment Management Inc. Acquires 50,000 Shares of Agenus Inc (NASDAQ:AGEN)

Oracle Investment Management Inc. boosted its holdings in shares of Agenus Inc (NASDAQ:AGEN) by 3.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,408,918 shares of the biotechnology company’s stock after buying an additional 50,000 shares during the period. Agenus makes up about 0.9% of Oracle Investment Management Inc.’s holdings, making the stock its 13th largest holding. Oracle Investment Management Inc.’s holdings in Agenus were worth $4,227,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of AGEN. BlackRock Inc. boosted its stake in Agenus by 11.0% during the second quarter. BlackRock Inc. now owns 9,294,627 shares of the biotechnology company’s stock valued at $27,884,000 after buying an additional 919,105 shares during the period. Vanguard Group Inc. raised its position in Agenus by 16.7% during the second quarter. Vanguard Group Inc. now owns 5,540,211 shares of the biotechnology company’s stock valued at $16,620,000 after purchasing an additional 793,180 shares in the last quarter. Alps Advisors Inc. purchased a new stake in Agenus during the second quarter valued at about $843,000. Strs Ohio purchased a new stake in Agenus during the second quarter valued at about $595,000. Finally, Chicago Equity Partners LLC purchased a new stake in Agenus during the second quarter valued at about $528,000. 35.96% of the stock is owned by institutional investors.

NASDAQ AGEN traded down $0.02 during trading hours on Friday, reaching $3.02. 403,694 shares of the stock traded hands, compared to its average volume of 704,289. The stock has a 50 day simple moving average of $2.79 and a two-hundred day simple moving average of $2.77. Agenus Inc has a 1 year low of $1.54 and a 1 year high of $3.88. The company has a market cap of $417.42 million, a price-to-earnings ratio of -2.10 and a beta of 1.84.



Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.05). The business had revenue of $15.72 million during the quarter, compared to analyst estimates of $5.37 million. On average, equities research analysts expect that Agenus Inc will post -1.04 earnings per share for the current fiscal year.

Separately, BidaskClub upgraded Agenus from a “sell” rating to a “hold” rating in a research report on Tuesday, September 10th.

Agenus Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Recommended Story: Does the discount rate affect the economy?

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc (NASDAQ:AGEN).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.